Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 4/2009

01-02-2009 | Case Report

Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis

Authors: Hatice Bodur, Filiz Eser, Şefika Konca, Serpil Arıkan

Published in: Rheumatology International | Issue 4/2009

Login to get access

Abstract

Infliximab is a chimerical monoclonal antibody currently used in the treatment of various inflammatory diseases. Lupus-like syndrome is a rarely reported adverse event, and generally observed in rheumatoid arthritis cases. We hereby define and describe a case of a lupus-like syndrome, which developed following the 4th infliximab infusion in a 62-year-old patient with ankylosing spondylitis (AS). As far as we acknowledge, the present case is the third AS case with infliximab-induced lupus.
Literature
1.
2.
3.
Zochling J, Braun J (2007) Quality indicators, guidelines and outcome measures in ankylosing spondylitis. Clin Exp Rheumatol 25(6) (Suppl 47):147–152
4.
Kang MJ, Lee YH, Lee J (2006) Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. J Korean Med Sci 21(5):946–949PubMedCrossRef
5.
De Bandt M, Sibilia J, Le Loët X et al (2005) Club Rhumatismes et Inflammation. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res Ther 7(3):545–551. doi:10.​1186/​ar1715 CrossRef
6.
Braun J, Baraliakos X, Listing J et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67(3):340–345. doi:10.​1136/​ard.​2007.​075879 PubMedCrossRef
7.
Van der Heijde D, Pangan AL, Schiff MH et al (2007) Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum 57(6):1050–1057
8.
9.
10.
11.
Metadata
Title
Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis
Authors
Hatice Bodur
Filiz Eser
Şefika Konca
Serpil Arıkan
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2009
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-008-0684-7

Other articles of this Issue 4/2009

Rheumatology International 4/2009 Go to the issue

Original Article

Bone mineral density in Indian women with rheumatoid arthritis

Case Report

Adalimumab-induced noncaseating granuloma in the bone marrow of a patient being treated for rheumatoid arthritis

Short Communication

NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis

Letter to the Editor

Periodontal disease in rheumatoid arthritis and Sjogren’s syndrome: a modifiable risk factor for atherosclerosis?

Original Article

Association of (−1,607) 1G/2G polymorphism of matrix metalloproteinase-1 gene with knee osteoarthritis in the Turkish population (knee osteoarthritis and MMPs gene polymorphisms)

Case Report

Necrotizing fasciitis in a patient treated with etanercept for dermatomyositis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits